When do biologic drug patents expire and when will biosimilars launch?

US Patent Family Members and Approved Drugs for World Intellectual Property Organization (WIPO) Patent: WO2016040940

These international patent data are derived from patent families, based on US drug-patent linkages. Accordingly, they should not be regarded as comprehensive records of ex-US drug-patent associations.

Glossary

Subscribe to access the full database, or Start Trial
US Patent Number	Estimated Patent Expiration	Generic Name	US Applicant	US Tradename
Start Trial	2034-09-12	urokinase	Microbix Biosystems	KINLYTIC
Start Trial	2034-09-12	asparaginase	Merck	ELSPAR
Start Trial	2034-09-12	interferon alfa-2b	Schering	INTRON A
Start Trial	2034-09-12	interferon alfa-n3	Interferon Sciences	ALFERON N INJECTION
Start Trial	2034-09-12	aldesleukin	Chiron	PROLEUKIN
Start Trial	2034-09-12	filgrastim	Amgen	NEUPOGEN
Start Trial	2034-09-12	sargramostim	Berlex Labs	LEUKINE
>US Patent Number	>Estimated Patent Expiration	>Generic Name	>US Applicant	>US Tradename

US Patent Family Members and Approved Drugs for World Intellectual Property Organization (WIPO) Patent: 2016040940

US Patent Family Members and Approved Drugs for World Intellectual Property Organization (WIPO) Patent: WO2016040940

Make Better Decisions: Try a trial or see plans & pricing